The American Medical Association (AMA) has approved new Category I CPT codes for Medtronic's Altaviva™ implantable tibial neuromodulation device and Symplicity Spyral™ renal denervation system. These devices treat urge urinary incontinence and uncontrolled hypertension, respectively, and the new codes, effective January 2028, reflect strong clinical evidence and physician adoption. The Altaviva™ device offers a minimally invasive, long-lasting treatment for urinary incontinence, while the Symplicity Spyral™ system provides a minimally invasive option for managing high blood pressure. These approvals support better reimbursement pathways and could enhance patient access to these innovative therapies.
Medtronic PLC shares are trading at USD 86.32 on Pluang, showing a slight decline of 0.88% as of Oct 02, 2026 03:12 WIB. The stock has a market cap of $110.38 billion and a dividend yield of 3.34%, with all current Pluang orders being buys.
Orchestra BioMed will hold an R&D Day on November 12, 2026, in New York City and via webcast to discuss clinical insights and development plans for its AVIM Therapy and Virtue SAB products. The event will feature company leaders and leading cardiolog...
Medtronic announced positive real-world results from global registries evaluating its Affera Mapping and Ablation System with Sphere-9 Catheter and PulseSelect Pulsed Field Ablation system. The studies involved over 2,200 patients with atrial fibrill...
